LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Lista de Ações・Incyte Corp

Incyte Corp

Fechado

SetorSaúde

99.8 2.32

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

97.27

Máximo

99.98

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	13.682 49.8
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 367M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+11.24% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	358M 19B
Abertura anterior	97.48
Fecho anterior	99.8

Sentimento de Notícias

By Acuity

67%

33%

309 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

59.52 / 62.66 Suporte e Resistência

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 23:41 UTC

Ganhos

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 de mai. de 2026, 21:40 UTC

Ganhos

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 de mai. de 2026, 23:12 UTC

Ganhos

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:07 UTC

Ganhos

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 de mai. de 2026, 23:05 UTC

Ganhos

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 de mai. de 2026, 23:04 UTC

Ganhos

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 de mai. de 2026, 22:25 UTC

Conversa de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 de mai. de 2026, 22:05 UTC

Conversa de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 de mai. de 2026, 21:58 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:47 UTC

Conversa de Mercado

Ganhos

Costco Posts 13% Sales Growth in April -- Market Talk

6 de mai. de 2026, 21:46 UTC

Ganhos

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 de mai. de 2026, 21:40 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:35 UTC

Conversa de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 de mai. de 2026, 21:32 UTC

Ações em Alta

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 de mai. de 2026, 21:29 UTC

Ganhos

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

11.24% parte superior

Previsão para 12 meses

Média 108.06 USD 11.24%

Máximo 135 USD

Mínimo 75 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

309 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation